Eton Pharmaceuticals Achieves Record-Breaking Second Quarter with 99% Revenue Growth and Significant Margin Expansion
On August 13, 2026, Eton Pharmaceuticals announced its exceptional second quarter financial results, showcasing record revenue growth, significant margin expansion, and notable progress across both its commercial portfolio and pipeline. The company's Chief Executive Officer, Sean Brynjelsen, highlighted several key accomplishments during the conference call.
The company achieved record revenue, delivering a 99% year-over-year growth with contributions from across the portfolio. This milestone was accompanied by significant margin expansion and accelerated adjusted EBITDA and net income growth. Furthermore, Eton established a strong commercial foundation in pediatric dermatology with the successful relaunch of HEMANGEOL, which is already performing ahead of expectations.
In addition to its commercial success, Eton expanded its portfolio through strategic transactions. The company acquired U.S. rights to IMPAVIDO and licensed ASN-001, adding both a commercial rare disease product and a late-stage development candidate that has the potential to become the largest product in their portfolio. These acquisitions demonstrate Eton's commitment to growing its business through shrewd investments.
From a research and development perspective, Eton had a productive few months. The company submitted a Prior Approval Supplement for the KHINDIVI label expansion, initiated the ET-700 pilot study, began preparations for the Increlex label harmonization study, and received Fast Track designation for Amglidia. These advancements underscore Eton's dedication to expanding its product offerings and improving patient care.
On the financial front, Eton reported revenue of $37.6 million, a 99% increase year-over-year. This growth was broad-based across their pediatric endocrinology franchise and Galzin. In light of this strong performance and favorable outlook for the remainder of the year, Eton raised its 2026 revenue guidance to exceed $145 million.
Profitability has always been a core focus at Eton, and the company's results reflect this emphasis. Adjusted EBITDA increased to $16.2 million or 43% of revenue, compared with $3.6 million or 16% of revenue in the prior year quarter. Even after new incremental expenses related to the ASN-001 transaction, Eton expects its full-year adjusted EBITDA margin to exceed 35%, up from their prior guidance of greater than 30%. As the company continues to grow revenue, it expects an increasing proportion of that growth to translate into earnings.
Eton's Chief Executive Officer, Sean Brynjelsen, noted during the conference call that the company is now seeing its model's scalability and operating leverage play out in financial results. As Eton continues to grow, it believes this business can generate an adjusted EBITDA margin above 50% in the long term.
